Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left"> </td><td align="center">Decitabine</td><td align="center">Low-dose cytarabine</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Cost per cycle of chemotherapy (INR)</td><td align="center">24,200</td><td align="center">1,600</td></tr><tr><td align="left">Total cost of therapy (median) (INR)</td><td align="center">96,800</td><td align="center">6,400</td></tr><tr><td align="left">Total cost of therapy (mean) (INR)</td><td align="center">95,186</td><td align="center">7146</td></tr><tr><td align="left">Simplified cost-effectiveness ratio (median)</td><td align="center">0.00022</td><td align="center">0.0034</td></tr><tr><td align="left">Simplified cost-effectiveness ratio (mean)</td><td align="center">0.00023</td><td align="center">0.0039</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Cost-effectiveness analysis of chemotherapy in the study groups.

Advances in Hematology

tab5

Table 5

Table 5: Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness 

Table 5 | Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness 